Related references
Note: Only part of the references are listed.AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS
Yehuda Handelsman et al.
ENDOCRINE PRACTICE (2016)
Lessons from the bedside: ketoacidosis and SGLT2 inhibitors
Yvonne Y. Chow et al.
MEDICAL JOURNAL OF AUSTRALIA (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
Karen Whalen et al.
CLINICAL THERAPEUTICS (2015)
SGLT2 Inhibitors May Predispose to Ketoacidosis
Simeon I. Taylor et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Hyperglycemic Crises in Adult Patients with Diabetes
Abbas E. Kitabchi et al.
DIABETES CARE (2009)
Share Paper
